Inventor · disambiguated record
Christopher Murawsky
Also filed as: MURAWSKY CHRISTOPHER M · Murawsky Christopher
7 granted patents·7 pending applications·29 citations·filing 2016–2025
82Inventor score
Files withAMGEN INC14
Top patents by PatentIndex Score
14 records- 0193US11530274B2Anti-STEAP1 antigen-binding proteinAMGEN INC·Filed 2019·Granted Dec 20, 2022·8 cites·72 claims
- 0291US10294303B2Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonistsAMGEN INC·Filed 2016·Granted May 21, 2019·12 cites·14 claims
- 0386US12252540B2Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)AMGEN INC·Filed 2021·Granted Mar 18, 2025·1 cites·5 claims
- 0486US11046774B2Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonistsAMGEN INC·Filed 2019·Granted Jun 29, 2021·5 cites·18 claims
- 0585US11066472B2Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereofAMGEN INC·Filed 2018·Granted Jul 20, 2021·3 cites·47 claims
- 0681US2025051457A1Asgr inhibitorsAMGEN INC·Filed 2024·Application pending·0 cites
- 0781US2024301087A1Anti-steap1 antigen-binding proteinAMGEN INC·Filed 2024·Application pending·0 cites
- 0876US2023159656A1Anti-steap1 antigen-binding proteinAMGEN INC·Filed 2022·Application pending·0 cites
- 0971US2025376529A1Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonistsAMGEN INC·Filed 2025·Application pending·0 cites
- 1069US2025154281A1Anti-steap1 antigen-binding proteinAMGEN INC·Filed 2025·Application pending·0 cites
- 1165US12331122B2Anti-ASGR-1 monoclonal inhibitory antibodiesAMGEN INC·Filed 2020·Granted Jun 17, 2025·0 cites·17 claims
- 1262US2024103009A1Non-terminal antibody discovery methods and single cell assaysAMGEN INC·Filed 2022·Application pending·0 cites
- 1347US12012462B2Chimeric receptors to DLL3 and methods of use thereofAMGEN INC·Filed 2019·Granted Jun 18, 2024·0 cites·14 claims
- 1441US2023137351A1Bispecific or biparatopic antigen binding proteins and uses thereofAMGEN INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher Murawsky files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →